ERBB2 and breast carcinoma: Significant attention is paid to preclinical andclinical studies of affibody conjugates with various radioisotopes for targetedradionuclide tumor imaging, which is particularly relevant in addressingchallenges encountered during the diagnosis and treatment of these patients.Clinical trials demonstrate that radiopharmaceuticals are well-tolerated andeffective for the assessment of tumor process prevalence and the determinationof HER2/neu status in breast cancer patients, supporting further research.